Fig 3. A2BR agonist failed to enhance Th17 response in TCR-δ^-/- mice.

Groups of B6 and TCR-δ^-/- mice (n = 6) were immunized with IRBP1-20/CFA alone or were also injected with an A2BR agonist (A2BR-A, BAY60-6583, 1mg/kg) via i.p., on days 1, 4, 7, and 10 post-immunization. On Day 13 post immunization, serum cytokine (IFN-γ and IL-17) levels measured by ELISA (A). IL-17⁺ and IFN-γ⁺ cells among the proliferating T cells were assessed after 5-day in vitro stimulation of CD3⁺ T cells with the immunizing peptides and APCs under Th1 (Upper panel) and Th17 (lower panel) polarizing conditions (B) 48-hour culture supernatants of the cells cultured in (B) were assessed for IL-17 and IFN-γ by ELISA (C). Data are from one single experiment, which are representative of three independent experiments. *p<0.05.